MedTrace Logo

Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial

NCT06700798 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-06-17

No results posted yet for this study

Summary

This study is a randomized, open-label, multicenter, prospective clinical trial aimed at evaluating the efficacy and safety of orelabrutinib combined with rituximab for the previously untreat MZL

Conditions

  • Marginal Zone Lymphoma(MZL)

Interventions

DRUG

Orelabrutinib

150mg po

DRUG

rituximab

375mg/m\^2, intravenous

DRUG

Cyclophosphamide

750mg/m\^2

DRUG

Vincristine

1.4mg/m\^2

DRUG

Prednisone tablet

60mg/m\^2

Sponsors & Collaborators

  • Fei Li

    lead OTHER

Principal Investigators

  • Fei Li, professor · The First Affiliated Hospital of Nanchang University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2026-05-04
Completion
2027-12-04

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06700798 on ClinicalTrials.gov